Celon Pharma S.A.

WSE:CLN Stock Report

Market Cap: zł1.2b

Celon Pharma Valuation

Is CLN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CLN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
zł76.11
Fair Value
70.2% undervalued intrinsic discount
5
Number of Analysts

Below Fair Value: CLN (PLN22.65) is trading below our estimate of fair value (PLN76.11)

Significantly Below Fair Value: CLN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLN?

Key metric: As CLN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CLN. This is calculated by dividing CLN's market cap by their current earnings.
What is CLN's PE Ratio?
PE Ratio65.9x
Earningszł18.51m
Market Capzł1.22b

Price to Earnings Ratio vs Peers

How does CLN's PE Ratio compare to its peers?

The above table shows the PE ratio for CLN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.3x
BGD Biogened
14.4xn/azł65.8m
SLV Selvita
16.9x16.9%zł915.0m
SVE Synthaverse
77.6xn/azł345.0m
4548 Seikagaku
16.2xn/aJP¥41.7b
CLN Celon Pharma
65.9x-33.9%zł1.2b

Price-To-Earnings vs Peers: CLN is expensive based on its Price-To-Earnings Ratio (65.9x) compared to the peer average (44.6x).

Price to Earnings Ratio vs Industry

How does CLN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
CLN 65.9xIndustry Avg. 22.7xNo. of Companies10PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CLN is expensive based on its Price-To-Earnings Ratio (65.9x) compared to the European Pharmaceuticals industry average (22.7x).

Price to Earnings Ratio vs Fair Ratio

What is CLN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio65.9x
Fair PE Ratio15x

Price-To-Earnings vs Fair Ratio: CLN is expensive based on its Price-To-Earnings Ratio (65.9x) compared to the estimated Fair Price-To-Earnings Ratio (15x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CLN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentzł22.65
zł27.64
+22.0%
32.5%zł39.00zł12.00n/a5
Feb ’26zł24.20
zł27.64
+14.2%
32.5%zł39.00zł12.00n/a5
Jan ’26zł26.45
zł27.64
+4.5%
32.5%zł39.00zł12.00n/a5
Dec ’25zł26.95
zł25.58
-5.1%
39.7%zł39.00zł12.00n/a5
Nov ’25zł27.80
zł26.38
-5.1%
39.7%zł39.00zł12.00n/a5
Oct ’25zł27.45
zł26.38
-3.9%
39.7%zł39.00zł12.00n/a5
Sep ’25zł31.70
zł21.10
-33.4%
45.7%zł39.00zł12.00n/a5
Aug ’25zł26.60
zł21.10
-20.7%
45.7%zł39.00zł12.00n/a5
Jul ’25zł15.80
zł16.78
+6.2%
21.2%zł23.00zł12.00n/a5
Jun ’25zł15.58
zł16.78
+7.7%
21.2%zł23.00zł12.00n/a5
May ’25zł15.16
zł16.93
+11.6%
23.3%zł23.00zł12.00n/a4
Apr ’25zł15.12
zł16.50
+9.1%
24.4%zł23.00zł12.00n/a4
Mar ’25zł15.08
zł16.88
+11.9%
23.9%zł23.00zł12.00n/a4
Feb ’25zł15.54
zł17.38
+11.8%
20.1%zł23.00zł14.00zł24.204
Jan ’25zł15.46
zł17.38
+12.4%
20.1%zł23.00zł14.00zł26.454
Dec ’24zł14.84
zł17.38
+17.1%
20.1%zł23.00zł14.00zł26.954
Nov ’24zł15.18
zł15.50
+2.1%
9.5%zł17.50zł14.00zł27.803
Oct ’24zł15.30
zł15.50
+1.3%
9.5%zł17.50zł14.00zł27.453
Sep ’24zł15.96
zł17.83
+11.7%
18.4%zł22.00zł14.00zł31.703
Aug ’24zł16.90
zł17.83
+5.5%
18.4%zł22.00zł14.00zł26.603
Jul ’24zł15.50
zł17.83
+15.1%
18.4%zł22.00zł14.00zł15.803
Jun ’24zł16.00
zł17.83
+11.5%
18.4%zł22.00zł14.00zł15.583
May ’24zł13.90
zł17.83
+28.3%
18.4%zł22.00zł14.00zł15.163
Apr ’24zł15.00
zł17.83
+18.9%
18.4%zł22.00zł14.00zł15.123
Mar ’24zł15.82
zł17.83
+12.7%
18.4%zł22.00zł14.00zł15.083
Feb ’24zł17.12
zł16.83
-1.7%
26.8%zł22.00zł11.00zł15.543
Analyst Price Target
Consensus Narrative from 5 Analysts
zł27.64
Fair Value
18.1% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/23 02:46
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celon Pharma S.A. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamil KliszczBiuro maklerskie mBanku
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Vladimira UrbankovaErste Group Bank AG